FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next
Executive Summary
HHS is planning a major overhaul of FDA's postmarketing surveillance system as the centerpiece of its next announcement about upgrades to the drug safety regulatory system
You may also be interested in...
IoM Report Blames FDA Leadership Crisis For Failure To Improve Drug Safety
The Institute of Medicine's report on the current state of FDA's drug safety regulation "may not fully reflect a lot of the changes that have been made" at the Center for Drug Evaluation & Research, Deputy Commissioner for Operations Janet Woodcock said Sept. 22
IoM Report Blames FDA Leadership Crisis For Failure To Improve Drug Safety
The Institute of Medicine's report on the current state of FDA's drug safety regulation "may not fully reflect a lot of the changes that have been made" at the Center for Drug Evaluation & Research, Deputy Commissioner for Operations Janet Woodcock said Sept. 22
One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA
One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs